Advertisement
Screener

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

MATINAS BIOPHARMA HOLDINGS, INC. Comprehensive Income

MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) reported Comprehensive Income of -$10.35 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.

Financial Statements › Income Statement › Unrealized Gains

us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-03-31

  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$1.91M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$1.53M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-06-30 was -$5.25M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-03-31 was -$1.66M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$10.35M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$24.03M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$22.34M.
  • MATINAS BIOPHARMA HOLDINGS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$21.68M.
Period endComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month as first filedComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 monthComprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month as first filed
2025-12-31-$1.91M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$3.44M
derived: sum of 2 quarters · filed 2026-03-31
-$8.69M
derived: sum of 3 quarters · filed 2026-03-31
-$10.35M
10-K · filed 2026-03-31
2025-09-30-$1.53M
10-Q · filed 2025-11-10
-$6.78M
derived: sum of 2 quarters · filed 2025-11-10
-$8.43M
10-Q · filed 2025-11-10
-$16.87M
derived: sum of 4 quarters · filed 2026-03-31
2025-06-30-$5.25M
10-Q · filed 2025-08-14
-$6.90M
10-Q · filed 2025-08-14
-$15.33M
derived: sum of 3 quarters · filed 2026-03-31
-$19.56M
derived: sum of 4 quarters · filed 2026-03-31
2025-03-31-$1.66M
10-Q · filed 2025-05-15
-$10.09M
derived: sum of 2 quarters · filed 2026-03-31
-$14.31M
derived: sum of 3 quarters · filed 2026-03-31
-$19.95M
derived: sum of 4 quarters · filed 2026-03-31
2024-12-31-$8.43M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$12.66M
derived: sum of 2 quarters · filed 2026-03-31
-$18.29M
derived: sum of 3 quarters · filed 2026-03-31
-$24.03M
10-K · filed 2026-03-31
2024-09-30-$4.22M
10-Q · filed 2025-11-10
-$9.86M
derived: sum of 2 quarters · filed 2025-11-10
-$15.60M
10-Q · filed 2025-11-10
-$20.77M
derived: sum of 4 quarters · filed 2025-11-10
2024-06-30-$5.64M
10-Q · filed 2025-08-14
-$11.37M
10-Q · filed 2025-08-14
-$16.55M
derived: sum of 3 quarters · filed 2025-08-14
-$22.45M
derived: sum of 4 quarters · filed 2025-08-14
2024-03-31-$5.74M
10-Q · filed 2025-05-15
-$10.91M
derived: sum of 2 quarters · filed 2025-05-15
-$16.81M
derived: sum of 3 quarters · filed 2025-05-15
-$22.79M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$5.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15
-$11.08M
derived: sum of 2 quarters · filed 2025-04-15
-$17.05M
derived: sum of 3 quarters · filed 2025-04-15
-$22.34M
10-K · filed 2025-04-15
2023-09-30-$5.90M
10-Q · filed 2024-11-13
-$11.88M
derived: sum of 2 quarters · filed 2024-11-13
-$17.16M
10-Q · filed 2024-11-13
-$20.69M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$5.98M
10-Q · filed 2024-08-14
-$11.26M
10-Q · filed 2024-08-14
-$14.79M
derived: sum of 3 quarters · filed 2024-08-14
-$20.43M
derived: sum of 4 quarters · filed 2024-08-14
2023-03-31-$5.28M
10-Q · filed 2024-05-09
-$8.81M
derived: sum of 2 quarters · filed 2024-05-09
-$14.45M
derived: sum of 3 quarters · filed 2024-05-09
-$20.50M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$3.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27
-$9.17M
derived: sum of 2 quarters · filed 2024-03-27
-$15.21M
derived: sum of 3 quarters · filed 2024-03-27
-$21.68M
10-K · filed 2024-03-27
2022-09-30-$5.64M
10-Q · filed 2023-11-08
-$5.64M
10-Q · filed 2022-11-02
-$11.69M
derived: sum of 2 quarters · filed 2023-11-08
-$18.15M
10-Q · filed 2023-11-08
-$18.15M
10-Q · filed 2022-11-02
-$25.00M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$6.05M
10-Q · filed 2023-08-09
-$6.05M
10-Q · filed 2022-08-11
-$12.51M
10-Q · filed 2023-08-09
-$12.51M
10-Q · filed 2022-08-11
-$19.35M
derived: sum of 3 quarters · filed 2023-08-09
-$26.24M
derived: sum of 4 quarters · filed 2023-08-09
2022-03-31-$6.46M
10-Q · filed 2023-05-10
-$6.46M
10-Q · filed 2022-05-12
-$13.31M
derived: sum of 2 quarters · filed 2023-05-10
-$20.19M
derived: sum of 3 quarters · filed 2023-05-10
-$25.07M
derived: sum of 4 quarters · filed 2023-05-10
2021-12-31-$6.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15
-$13.73M
derived: sum of 2 quarters · filed 2023-03-15
-$18.61M
derived: sum of 3 quarters · filed 2023-03-15
-$23.66M
10-K · filed 2023-03-15
-$23.66M
10-K · filed 2022-03-08
2021-09-30-$6.89M
10-Q · filed 2022-11-02
-$11.77M
derived: sum of 2 quarters · filed 2022-11-02
-$16.81M
10-Q · filed 2022-11-02
-$23.29M
derived: sum of 4 quarters · filed 2022-11-02
2021-06-30-$4.88M
10-Q · filed 2022-08-11
-$9.92M
10-Q · filed 2022-08-11
-$16.40M
derived: sum of 3 quarters · filed 2022-08-11
-$21.96M
derived: sum of 4 quarters · filed 2022-08-11
2021-03-31-$5.05M
10-Q · filed 2022-05-12
-$11.52M
derived: sum of 2 quarters · filed 2022-05-12
-$17.09M
derived: sum of 3 quarters · filed 2022-05-12
-$22.74M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$6.48M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-03-11
-$12.04M
derived: sum of 2 quarters · filed 2022-03-11
-$17.70M
derived: sum of 3 quarters · filed 2022-03-11
-$22.22M
10-K/A · filed 2022-03-11
2020-09-30-$5.56M
10-Q · filed 2021-11-08
-$11.22M
derived: sum of 2 quarters · filed 2021-11-08
-$15.74M
10-Q · filed 2021-11-08
-$21.32M
derived: sum of 4 quarters · filed 2021-11-08
2020-06-30-$5.66M
10-Q · filed 2021-08-10
-$10.18M
10-Q · filed 2021-08-10
-$15.75M
derived: sum of 3 quarters · filed 2021-08-10
-$20.16M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31-$4.52M
10-Q · filed 2021-05-10
-$10.10M
derived: sum of 2 quarters · filed 2021-05-10
-$14.50M
derived: sum of 3 quarters · filed 2021-05-10
-$17.85M
derived: sum of 4 quarters · filed 2021-05-10
2019-12-31-$5.57M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29
-$9.98M
derived: sum of 2 quarters · filed 2021-03-29
-$13.32M
derived: sum of 3 quarters · filed 2021-03-29
-$17.37M
10-K · filed 2021-03-29
2019-09-30-$4.40M
10-Q · filed 2020-11-06
-$7.75M
derived: sum of 2 quarters · filed 2020-11-06
-$11.80M
10-Q · filed 2020-11-06
2019-06-30-$3.34M
10-Q · filed 2020-08-10
-$7.40M
10-Q · filed 2020-08-10
2019-03-31-$4.05M
10-Q · filed 2020-05-11
2018-12-31-$14.08M
10-K · filed 2020-03-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
Genprex, Inc. (GNPX)United States$0.003B-0.02
Alaunos Therapeutics, Inc. (TCRT)United States$0.003B-1.44
ORAGENICS INC (OGEN)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B